Abstract
Background A 48-year-old man presented to a neurologist with complaints of bilateral hearing loss and tinnitus. The patient was a member of a large family affected by neurofibromatosis type 2 and first noted hearing loss 10 years before presentation.
Investigations Medical and neurological examination, MRI scan of the brain and spinal cord, pure-tone audiometry, NU–6 monosyllabic word test with phoneme scoring, City University of New York topic-related sentences test, noise/voice test of minimal auditory capability battery.
Diagnosis Progressive neurofibromatosis-type-2-related vestibular schwannomas.
Management Annual cranial MRI and audiology, surgical resection of right vestibular schwannoma, high-power behind-the-ear hearing aid, erlotinib therapy for progressive left vestibular schwannoma.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cellular mechanisms of heterogeneity in NF2-mutant schwannoma
Nature Communications Open Access 21 March 2023
-
Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality
Child's Nervous System Open Access 16 June 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout


References
Curto M et al. (2007) Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 177: 893–903
Sorensen AG et al. (2001) Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 19: 551–557
American National Standards Institute (2004) Methods for manual pure-tone threshold audiometry. S3.21 New York: ANSI
Boothroyd A and Calkwell S (1981) Vibrotactile thresholds in pure-tone audiometry. In Hearing Measurement: a Book of Readings, edn 2 134–139 (Eds Chaiklin JB. et al.) New York: Addison Wesley
Halpin C: Measuring audiometric outcomes. In Evidence Based Otolaryngology 227–238 (Eds Shin J. et al.) New York: Springer, in press
Owens E et al. (1982) Interim assessment of candidates for cochlear implants. Arch Otolaryngol 108: 478–483
Boothroyd A et al. (1988) Voice fundamental frequency as an auditory supplement to the speechreading of sentences. Ear Hear 9: 306–312
Farrell CJ and Plotkin SR (2007) Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel–Lindau, and other syndromes. Neurol Clin 25: 925–946
Evans DG et al. (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10 year period: higher incidence than previously thought. Otol Neurotol 26: 93–97
Mulvihill JJ et al. (1990) NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 113: 39–52
National Institutes of Health Consensus Development Conference (1988) Neurofibromatosis. Conference statement. Arch Neurol 45: 575–578
Baser ME et al. (2002) Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59: 1759–1765
Evans DG et al. (2005) Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 19: 5–12
Otto SR et al. (2002) Multichannel auditory brainstem implant: update on performance in 61 patients. J Neurosurg 96: 1063–1071
Mathieu D et al. (2007) Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 60: 460–468
Rowe JG et al. (2003) Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry 74: 1288–1293
Evans DG et al. (2006) Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 43: 289–294
Shepherd FA et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132
Acknowledgements
This work was supported in part by grants from the Department of Defense NF050202 and from Neurofibromatosis, Inc., New England (SRP), and by a grant from the Children's Tumor Foundation (GJH). The authors wish to acknowledge the past members of the Massachusetts General Hospital Neurofibromatosis Clinic including Priscilla Short, MD, Mia MacCollin, MD, Catherine Bove, RN, and Robert Martuza, MD, for their care of patients with NF2. Désirée Lie, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the Medscape-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Plotkin, S., Singh, M., O'Donnell, C. et al. Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Rev Clin Oncol 5, 487–491 (2008). https://doi.org/10.1038/ncponc1157
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1157
This article is cited by
-
Cellular mechanisms of heterogeneity in NF2-mutant schwannoma
Nature Communications (2023)
-
Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality
Child's Nervous System (2020)
-
Search for Chemical Compounds for Pharmacotherapy of Neurofibromatosis Type 2
Pharmaceutical Chemistry Journal (2015)
-
Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter
Cancer Gene Therapy (2010)